ALDH1A3-IN-1 (Compound 14) is a potent ALDH1A3 inhibitor, with an IC50 of 0.63 µM and a Ki of 0.46 µM. ALDH1A3-IN-1 can be studied in prostate cancer[1].
ALDH1A3-IN-1 (Compound 14) (0-200 µM, 96 h) shows antiproliferative activity in prostate cancer cell lines[1].
ALDH1A3-IN-1 (0-200 µM, 72 h) reduces cell viability of primary prostate cells in a dose-dependent manner[1].
Cell Proliferation Assay[1]
| Cell Line: | PC3, LNCaP, and DU145 cells |
| Concentration: | 12.5-200 µM |
| Incubation Time: | 96 h |
| Result: | Showed antiproliferative activity with IC50 values of 47 ± 6, 25 ± 1, and 61 ± 5 µM against PC3, LNCaP, and DU145 cells. |
Cell Viability Assay[1]
| Cell Line: | Primary cells cultured at early passage from human prostate tissue biopsies |
| Concentration: | 50 and 200 μM |
| Incubation Time: | 72 h |
| Result: | Resulted a dose-dependent reduction in percentage cell viability of primary prostate epithelial cultures. |
[1]. Ali I M Ibrahim, et al. Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer. J Med Chem. 2022 Mar 10;65(5):3833-3848.